|Bid||11.50 x 150000|
|Ask||12.10 x 150000|
|Day's range||11.60 - 11.60|
|52-week range||11.10 - 18.10|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||08 Feb 2023 - 13 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has closed a secured convertible credit agreement (the "credit agreement") with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross p
In the latest trading session, Innoviva (INVA) closed at $13.27, marking a +0.15% move from the previous day.
In the latest trading session, Innoviva (INVA) closed at $13.03, marking a -1.06% move from the previous day.